(Reuters) – The U.S. government will buy 1.25 million additional doses of Regeneron Pharmaceuticals’ COVID-19 antibody cocktail for about $2.63 billion, bringing the total supply of the treatment to over 1.5 million doses.
Regeneron’s dual antibody therapy for COVID-19 will likely be effective against new variants of the coronavirus identified so far in a handful of countries, the company had said on Monday.
(Reporting by Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)
